ABSTRACT
I
nfection with hepatitis C virus (HCV) is one of the leading causes of acute and chronic liver disease. Worldwide, 130 million to 170 million people are chronically infected, representing approximately 2 to 3% of the world's population. Despite the enormous success of new antiviral drugs directly acting against HCV, the high costs of these drugs and barriers to treatment of groups at high risk for HCV infection limit their widespread use in many parts of the world (1, 2) . Therefore, development of an effective vaccine to prevent chronic HCV infection still remains a major goal. Both innate and adaptive immunity are essential to control HCV infection; however, only a minority of infected patients achieves spontaneous clearance of the virus, whereas most patients develop chronic hepatitis, associated with the risk of progressive liver disease. In cases where the virus is cleared spontaneously, resolution of reinfection occurs more rapidly (3), indicating that HCV-specific memory immune responses positively impact disease control. Hence, a potent vaccine inducing robust T cell responses could provide significant clinical benefit.
There is strong evidence that CD8 ϩ T cells are an essential component of a successful immune response against HCV during acute infection (3), even though inherent viral sequence diversity is a major obstacle to vaccine design against hepatitis C (4). So far, seven different genotypes and multiple subtypes have been described (5) . Moreover, even isolates of the same HCV subtype are highly polymorphic between individuals. In the context of HLA allelic restriction, this high sequence diversity thus represents the main barrier for immune control. Even in conserved regions of the HCV polyprotein, most CD8 ϩ T cell epitopes differ between HCV genotypes (6) . Accordingly, the majority of CD8 ϩ T cell responses is directed against one genotype only and shows little cross-reactivity with other genotypes (6) . Indeed, the protective effect of beneficial HLA alleles such as HLA-B*27 and HLA-B*57 was limited to certain HCV genotypes and subtypes (7, 8) , and there is strong evidence that the sequence of immunodominant CD8 T cell epitopes upon viral transmission impacts the outcome of HCV infection (9) .
The CD8 ϩ T cell compartment is characterized by a highly diverse and individualized T cell receptor (TCR) repertoire as a consequence of random gene reassortment. Here, we hypothesized that different sequence variants of an immunodominant CD8 ϩ T cell epitope, all binding with high affinity to HLA class I, target different TCR repertoires and thereby influence the quality of the CD8 ϩ T cell response. By utilizing different peptides corresponding to naturally occurring variants of the HLA-A*02-restricted HCV epitope NS3 1406 -1415 for CD8
ϩ T cell priming in vitro, we addressed whether differences in the TCR repertoire for the respective peptides can be viewed as a reflection of different immunogenic properties associated with different CD8 ϩ T cell cross-reactivities. This epitope was previously reported to be immunodominant in the context of HLA-A*02 (10) . The genotype 1a prototype sequence (KLVALGINAV) is the most commonly used sequence in human immunology studies of HCV infection for identification of HCV-specific CD8 ϩ T cells (http://www.iedb .org/) (11) , and selection of escape mutations associated with a lack of immunogenicity has been reported for genotype 1a (12) . Notably, the epitope region is highly polymorphic in genotypes 1a and 1b. Although CD8 ϩ T cell responses against the most frequent variants of both subtypes have been reported (http://www.iedb .org/) (11), the exact differences in immunogenicity of the epitope variants are unknown. To address this, HCV NS3 1406 -1415 sequence variants were selected from the HCV sequence database (13), including two genotype 1a and three genotype 1b variants. In addition, a fourth genotype 1b variant under reproducible selection pressure by CD8 ϩ T cells from a large single-source outbreak was included (14) . Our data demonstrate that there are substantial differences in priming and cross-reactivity of CD8 ϩ T cells between the variants.
MATERIALS AND METHODS
Study subjects. Buffy coats were obtained from HLA-A*02:01-positive, HCV-seronegative, healthy blood donors at the Institute of Transfusion Medicine, University Hospital Essen, and peripheral blood mononuclear cells (PBMCs) were extracted by Ficoll gradient centrifugation. Highresolution HLA-A typing was performed by using commercially available sequence-specific oligonucleotides (High Definition LABType methodology; One Lambda Inc., Canoga Park, CA, USA). Additional blood samples from people who inject drugs (PWID) were collected from the ward for inpatient detoxification treatment of drug addicts or the clinic for opioid maintenance treatment (OMT) at the Department of Addictive Behavior and Addiction Medicine of the LVR-Hospital Essen, Hospital of the University of Duisburg-Essen. Written informed consent was obtained from all participants, and the study was approved by the ethics committee of the Medical Faculty of the University of Duisburg-Essen. Anti-HCV-seropositive, HLA-A*02-positive PWID (with or without detectable HCV RNA) were selected for analysis. Low-resolution HLA typing of blood samples from PWID was also performed by using LABType methodology (One Lambda Inc., Canoga Park, CA, USA).
Analysis of peptide binding to HLA-A*02:01. Peptide binding to HLA-A*02:01 was determined at Sanquin Blood Supply (Amsterdam, The Netherlands) as described previously (15) . Briefly, peptide exchange was assayed by using the PeliChange p*HLA-A*0201 kit (catalog number M2802; Sanquin) and the PeliScreen HLA class I enzyme-linked immunosorbent assay (ELISA) kit (catalog number M1924; Sanquin). Peptideexchange reactions were performed by exposure of conditional peptide/ HLA (pHLA) complexes to long-wavelength UV by using a 366-nm UV lamp (Camag, Muttenz, Switzerland), in the absence or presence of the indicated peptide (50 M). Subsequently, peptide-exchange efficiency was analyzed by using the PeliScreen HLA class I ELISA kit. This ELISA determines the presence of intact HLA class I complexes in an exchange reaction mixture. The following control peptides were used: NLVPMV ATV, a high-affinity binder to HLA-A*02:01, and CTELKLSDY, an HLA-A*01:01 ligand with no substantial affinity for HLA-A*0201. The absorbance of all peptides was evaluated relative to that of the high-affinity binder, which was set at 100%.
In vitro priming of naive CD8 ؉ T cells. In vitro CD8 ϩ T cell priming was performed as previously described (16, 17) . Briefly, monocytes were isolated by adherence to plastic and differentiated with 1,000 U/ml interleukin-4 (IL-4) and 800 U/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) (Peprotech) in Cellgenix DC medium (Cellgenix) supplemented with 0.4% penicillin-streptomycin (PAA, Austria) and 1% naturally coagulated human serum (PAA, Austria). After 72 h, immature monocyte-derived dendritic cells (moDCs) were matured by using 100 U/ml gamma interferon (IFN-␥) (Peprotech), 100 ng/ml lipopolysaccharide (LPS) (Sigma), and antigenic peptides at a concentration of 2 g/ml overnight. All peptides were synthesized by EMC Microcollections (Tübingen, Germany), with a purity of Ն95%. Naive CD8 ϩ T cells were isolated by negative selection utilizing a CD8 ϩ T cell isolation kit, followed by depletion of CD57
Ϫ and CD45RO-positive cells using microbeads (Miltenyi Biotech) according to the manufacturer's instructions. Purified naive CD8
ϩ T cells were supplemented with 5 ng/ml IL-7 (Peprotech) and maintained overnight. The next day, mature moDCs were harvested and exposed to 30 Gy of irradiation. CD8 ϩ T cells cultured overnight were mixed with moDCs at a ratio of 4:1 in T cell medium (Cellgenix DC medium supplemented with 0.4% penicillin-streptomycin and 5% human serum) supplemented with 30 ng/ml IL-21 (Peprotech). Fresh medium containing 5 ng/ml IL-7 and IL-15 (Peprotech) was added after 72 h and subsequently every 2 to 3 days. After 10 and 19 days, cocultures were restimulated by using irradiated, autologous, peptide-pulsed PBMCs. After restimulation, fresh medium supplemented with 100 U/ml IL-2 (Roche) and 5 ng/ml IL-7 and IL-15 was added after 48 h and subsequently every 2 to 3 days. Cells were analyzed after 27 days either by direct staining with HLA-A*02/peptide dextramers (fluorescently labeled phycoerythrin [PE] major histocompatibility complex [MHC] class I dextramers; Immudex, Copenhagen, Denmark) or by functional analysis.
Functional analysis of in vitro-primed CD8 ؉ T cells. For functional analysis, cells were harvested and stimulated with 1 ϫ 10 5 autologous, peptide-pulsed monocytes at a 1:2 ratio of monocytes to T cells or with synthetic peptide (10 g/ml) in the presence of 100 ng/ml brefeldin A. After 5 h of stimulation, cells were stained with viability stain (eFluor780) as well as CD8 (Alexa 700) and CD4 (PE-CF594) antibodies, followed by permeabilization and staining for IFN-␥ (fluorescein isothiocyanate [FITC] ). For analyses of polyfunctionality, cells were restimulated in the presence of brefeldin A and 1.25 g/ml anti-CD107a for 5 h. Subsequently, cells were stained for CD4 (allophycocyanin [APC]-eFluor780) and CD8 (eFluor450) and with viability dye (eFluor506). After fixation and permeabilization, the cells were additionally stained with IFN-␥ (FITC), IL-2 (peridinin chlorophyll protein [PerCP]-eFlour710), macrophage inflammatory protein 1 beta (MIP1␤) (PE-Cy7), and tumor necrosis factor alpha (TNF-␣) (APC). Antibodies were purchased from eBioscience (San Diego, CA, USA) or BD Pharmingen (Heidelberg, Germany) and used at optimal staining concentrations. Cells were analyzed by using a FACSCalibur or FACSCanto II flow cytometer (BD Pharmingen) or a Navios flow cytometer (Beckman Coulter) and results were analyzed with FlowJo software (Treestar, Ashland, OR). Polyfunctionality of primed CD8 ϩ T cells was examined in selected experiments. Peptide-specific CD8 ϩ T cells were simultaneously stained with specific antibodies and analyzed by flow cytometry. Data were further analyzed by using Pestle and SPICE software (18) .
Expansion of peptide-specific CD8
؉ T cells in people who inject drugs. Cryopreserved PBMCs from PWID were used to expand peptidespecific CD8 ϩ T cells. PBMCs were cultured in complete medium (RPMI 1640 containing 10% fetal calf serum, 100 U/ml penicillin, 100 g/ml streptomycin, and 100 M HEPES buffer) supplemented with 1 g/ml peptide, 25 U/ml IL-2, and 0.1 g/ml anti-CD28 and anti-CD49d (BD Pharmingen). After 10 days, specific cells were analyzed for IFN-␥ secretion by intracellular cytokine staining, as described above.
Analysis of the T cell receptor V␤ repertoire of peptide-specific CD8 ؉ T cells. Antigen-specific T cells were further analyzed by using an antibody panel directed against 24 different individual variable beta (V␤) chains of the TCR. The panel contained V␤1 PE, V␤2 FITC, V␤3 FITC, V␤4 FITC, V␤5.2 PE, V␤7.1 PE, V␤7.2 PE, V␤11 APC, V␤12 FITC, V␤13.6 PE, V␤14 PE, V␤16 FITC, V␤17 PE, V␤18 PE, V␤20 FITC, V␤21.3 FITC, and V␤22 FITC antibodies (all purchased from Beckman Coulter) as well as V␤5.1 APC, V␤5.3 APC, V␤8 eFluor450, V␤9 APC, V␤13.1 FITC, V␤13.2 PE, and V␤23 PerCP-eFluor710 antibodies (all obtained from eBioscience), covering approximately 70% of the V␤ repertoire. Cells were stained simultaneously with antibodies against CD4 (APC-eFluor780), CD8 (eFluor450 or APC), and IFN-␥ (PE-Cy7), a set of 2 to 3 antibodies directed against TCR V␤ families, as well as a viability stain (eFluor506). CD8 ϩ T cells responding to peptide restimulation were selected based on their IFN-␥ secretion and further analyzed for their V␤ usage by using a FACSCanto II instrument.
Sequence analysis of the NS3 1406 -1415 epitope. All available HCV genotype 1b NS3 sequences were retrieved from the public HCV sequence database (13) . Identical sequences and sequences of unknown origin were removed, and additional sequences obtained in Germany and China were added and aligned by using Geneious 7.0.6 (Biomatters, Auckland, New Zealand). A phylogenetic tree was calculated by utilizing the neighborjoining method and the Jukes-Cantor distance model, as implemented in Geneious 7.0.6 software. The resulting tree was edited with FigTree software (available at http://tree.bio.ed.ac.uk/). Branches were transformed into a cladogram, and sequences from Japan and China are shown in red.
RESULTS

Frequent variants of HCV epitope NS3
1406 -1415 bind with high affinity to HLA-A*02:01. The most frequent sequence variants of the immunodominant HLA-A*02-restricted CD8 ϩ T cell epitope of HCV (NS3 1406 -1415 ) were selected from a public HCV sequence database ( Table 1) . The most frequent sequence of this epitope in genotype 1a is KLVALGINAV (gt1a_1) (43.3% of the genotype 1a sequence entries in the database), which is also the most frequently used variant in studies of HCV immunology (11 gt1b_AD] ), which was the source sequence from a large HCV genotype 1b outbreak, was included in this study. A previous study of HLA class I-associated viral evolution in this outbreak suggested that this sequence was under strong immune pressure in HLA-A*02-positive patients (14) .
All six variants were predicted to bind with high affinity to HLA-A*02:01 in a prediction algorithm implemented in the Immune Epitope Database (IEDB) (http://tools.immuneepitope.org /mhci/), with the exception of the epitope variant gt1b_AD, which was predicted to bind with intermediate affinity (Table 1) . Binding to HLA-A*02:01 was experimentally tested by HLA stabilization assays using UV-induced peptide exchange (Fig. 1) . The positive-control peptide used in this assay represents a high-affinity ligand of HLA-A*02:01 (NLVPMVATV). All six variants of the NS3 1406 -1415 epitope showed binding of Ͼ100% compared to the positive control, showing that they all bind to HLA-A*02:01 with high affinity.
Sequence variants of HCV epitope NS3 1406 -1415 show distinct reproducibility of CD8
؉ T cell priming in vitro. Most analyses of HCV-specific CD8 ϩ T cells are focused on memory T cells expanded or isolated from anti-HCV-seropositive donors. In this epitope were analyzed for their specific binding to HLA-A*02:01 by a peptideexchange assay. After induction of degradation of a conditional reference peptide in complex with HLA-A*02:01 by UV light, the peptide-exchange rate with selected ligands was determined by an ELISA that detects intact pHLA complexes. A high-affinity binder to HLA-A*02:01 (NLVPMVATV) and an HLA-A*01:01 ligand with no substantial affinity for HLA-A*02:01 (CTELKL SDY) served as positive (Pos) and negative (Neg) controls, respectively. "UV" indicates the ELISA results for pHLA complexes upon exposure to UV light in the absence of peptide. The absorbance of all peptides was evaluated relative to that of the high-affinity binder, which was set at 100%.
setting, the exact sequence at the time of transmission is typically unknown; hence, the impact of epitope variants on the recruited CD8 ϩ T cell repertoire is difficult to address. Here, the goal was to prime and expand HCV-specific T cells from an unaltered repertoire of naive CD8 ϩ T cells and to address whether priming and cross-reactivity are influenced by sequence variants. Therefore, peptide-loaded moDCs were used for priming of naive CD8 ϩ T cells from HLA-A*02:01-positive, anti-HCV-and HCV RNAnegative healthy blood donors. After 27 days of culture, including two additional restimulations, the frequency of primed NS3 1406 -1415 -specific CD8 ϩ T cells was analyzed by using MHC class I multimers in 6 donors (donors D5 to D11) ( Fig. 2A) and by analysis of IFN-␥-secreting CD8 ϩ T cells upon peptide restimulation in all 11 donors (Fig. 2B) . The frequencies of successful priming of naive CD8 ϩ T cells differed between the peptide variants tested. Overall, priming was more reproducible with the genotype 1b variants than with the genotype 1a variants. In genotype 1a, the prototype sequence (gt1a_1) showed better priming potential than the gt1a_2 variant. Interestingly, the most frequent genotype 1b variant (gt1b_1) was associated with less reproducible priming than the other three genotype 1b variants. Figure 2C summarizes the frequencies of successful priming (defined as a minimum of 0.5% IFN-␥-secreting CD8 ϩ T cells upon peptide restimulation) for all experiments. Due to limitations in cell yields in some experiments, not all peptides were tested in duplicate throughout all experiments. Priming was most frequently successful when the genotype 1b variants gt1b_3 (55% success rate) and gt1b_AD (40% success rate) were used. Of note, in some cases, there was a drastic discrepancy between the numbers of peptide-specific CD8 ϩ T cells assessed with HLA class I multimers and the percentage of IFN-␥-producing cells (e.g., donor D5 primed with gt1a_1). Therefore, the polyfunctionality of in vitro-primed peptide-specific CD8 ϩ T cell responses directed against the variants gt1a_1 and gt1b_3 was characterized in parallel by analysis of four different cytokines (IFN-␥, TNF-␣, IL-2, and MIP1␤) and the degranulation marker CD107a in one donor. Figure 2D shows the distribution of specific CD8 ϩ T cells with 1, 2, 3, 4, and 5 effector functions upon stimulation with high peptide concentrations (10 g/ml). Here, CD8 ϩ T cells primed with the epitope variant gt1b_3 showed superior functionality compared to CD8 ϩ T cells primed with the variant gt1a_1.
CD8 ؉ T cells primed with sequence variants of HCV epitope NS3 1406 -1415 show distinct cross-reactivity. Next, the cross-reactivity of the in vitro-primed CD8 ϩ T cells against the different sequence variants of the NS3 1406 -1415 epitope was analyzed. Therefore, cultured CD8 ϩ T cells were restimulated with all variants, and the percentage of IFN-␥-producing cells was determined. Figure 3A exemplifies the differences in cross-reactivity obtained for in vitro-primed CD8 ϩ T cells from one donor. CD8 ϩ T cells were primed with peptide gt1b_3, resulting in 1.72% IFN-␥-producing cells upon restimulation with gt1b_3 (Fig. 3A, left) . Similar frequencies of IFN-␥-producing cells were observed upon restimulation with the other genotype 1b variants, indicating full cross-reactivity with these genotype 1b variants, even though there was no cross-reactivity with the genotype 1a variants. In contrast, although, in the same donor, high frequencies of CD8 ϩ T cells specific for the variant gt1b_AD were primed (Fig. 3A, right) , these cells were not cross-reactive with any other epitope variant. The patterns of cross-reactivity were highly reproducible across different experiments: CD8 ϩ T cells primed with the epitope vari- ant gt1b_AD were never cross-reactive with other variants of the epitope, whereas the highest degree of cross-reactivity was observed for CD8 ϩ T cells primed with the epitope variant gt1b_2 or gt1b_3 (Fig. 3B) . Importantly, primed CD8 ϩ T cells seemed to exclusively react with variants of the same subtype. This was most evident for CD8 ϩ T cells primed with gt1b variants, which are almost not reactive with the gt1a variants, indicating that these cells are subtype specific (Fig. 3B) .
Cross-reactive CD8 ؉ T cells primed with gt1b_3 utilize a broader TCR V␤ repertoire. To address the difference between T cells with high cross-reactivity primed with gt1b_3 and T cells with low cross-reactivity primed with gt1b_AD, TCR V␤ chain profiles were assessed by flow cytometry utilizing specific antibodies. We selected a single donor to prime CD8 ϩ T cells in parallel with either the gt1b_3 variant or the gt1b_AD variant. Consistent with the results described above, in two experiments, CD8
ϩ T cells primed with gt1b_3 were cross-reactive with gt1b_1 (Fig. 4A) , whereas, as expected, CD8
ϩ T cells primed with gt1b_AD did not react with gt1b_3 or gt1b_1 (Fig. 4C) . Analysis of the TCR V␤ profiles revealed recruitment of multiple TCR V␤ chains for the 
CD8
ϩ T cell response against the gt1b_3 variant (Fig. 4B ). Although there was a large overlap between the two priming experiments with the same peptide variant, some TCR V␤ chains, such as V␤ 20 and V␤ 22, were expanded in one experiment only (Fig.  4B, top and bottom) . In contrast, CD8
ϩ T cells primed with the gt1b_AD variant were characterized by a more restricted repertoire (mainly TCR V␤ 3 and V␤ 5.1) (Fig. 4D) . Importantly, when CD8 ϩ T cells primed with the gt1b_3 variant were restimulated with the gt1b_1 variant, the same TCR V␤ repertoire was observed, suggesting that cross-reactivity was determined at the level of individual TCR V␤ chains. CD8 ؉ T cells specific for gt1b_3 show broader cross-reactivity in PWID exposed to HCV. We next addressed whether similar cross-reactivity patterns were present in memory CD8
ϩ T cells of HCV-exposed patients. We therefore analyzed the NS3 1406 -1415 -specific CD8
ϩ T cell response in 12 HLA-A*02-positive patients from a cohort of PWID, including 6 PWID infected with HCV genotype 1 and 6 anti-HCV-positive PWID without detectable HCV RNA. Previous studies suggested that PWID from this cohort are highly exposed to HCV genotypes 1 and 3, although the exact sequence at the time of transmission and priming of CD8 ϩ T cell responses is unknown. Upon antigen-specific expansion by a standard protocol with the gt1a_1, gt1b_1, or gt1b_3 peptide, CD8 ϩ T cell responses were detectable by intracellular IFN-␥ staining in seven PWID (Fig. 5) . In four patients, IFN-␥-producing cells were detectable upon expansion with gt1a_1. Notably, these CD8 ϩ T cells showed almost no cross-reactivity with the two other genotype 1b variants tested. Similar to the results of the in vitro priming experiments, IFN-␥-producing CD8 ϩ T cells were most reproducibly expanded in the presence of the variant gt1b_3 (5 of 12 PWID). Furthermore, in all cases, these CD8 ϩ T cells were to some degree cross-reactive with both of the other tested peptides, including the genotype 1a variant. The superiority of the gt1b_3 variant was most obvious in HCV RNA-negative patient IDU172. Here, a strong and fully cross-reactive CD8 ϩ T cell response was detectable after expansion in the presence of gt1b_3, whereas no IFN-␥-producing CD8 ϩ T cells were detected after expansion in the presence of any of the other peptides.
The gt1b_3 variant is predominantly observed in HCV isolates from Asia. We next wanted to know if there are populationbased differences in the frequencies of sequence variants of the NS3 1406 -1415 epitope. We were particularly interested in the gt1b_3 variant, as this was the most immunogenic epitope variant in our studies. All genotype 1b NS3 sequences of known origin were retrieved from a public database and aligned together with additional sequences obtained from isolates collected in Germany and China. A phylogenetic tree of all genotype 1b sequences revealed distinct clusters (Fig. 6) , with most sequences collected in Asia (mainly China and Japan [shown in red in Fig. 6 ]) branching together. Notably, sequences carrying the variant gt1b_3 (marked with dots in the tree) were highly enriched in HCV genotype 1b isolates of Asian origin. Twenty-six of 129 sequences (20.1%) from Asia carried the gt1b_3 sequence; in contrast, only 12 of 315 sequences (3.8%) collected outside Asia (mainly Europe and North America) carried this variant (P ϭ 2 ϫ 10 Ϫ7 ), suggesting that the gt1b_3 variant is more common in Asia.
DISCUSSION
HCV remains a global health challenge, but effective vaccine design is still hindered by its inherent sequence diversity. The existence of multiple genotypes and subtypes and innumerable variants at the quasispecies level calls for novel strategies to carefully select the optimal antigen for prophylactic immunization strategies. A successful vaccine needs to cope with the enormous antigen diversity, for example, by identifying and targeting the immune response to conserved regions of the virus. However, CD8
ϩ T cell epitopes that are conserved across genotypes are rare in HCV (6) . Alternatively, a successful vaccine should activate multiple different CD8 ϩ T cell responses against different sequence variants of important epitopes (19) or should prime CD8 ϩ T cells with highly cross-reactive TCRs that interact with multiple sequence variants. The latter would possibly also be advantageous for prevention of selection of immune escape mutations (20, 21) , which strongly contributes to viral persistence during acute infection (22) (23) (24) (25) .
Here, we show that naturally circulating sequence variants of the immunodominant HLA-A*02-restricted CD8 ϩ T cell epitope NS3 1406 -1415 , all binding to HLA-A*02:01 with similar affinities, are associated with reproducible differences regarding the success rate of in vitro priming and the cross-reactivity of primed CD8 ϩ T cells. Different peptide variants in complex with HLA-A*02:01 presumably engage different TCRs. Although not tested here, this could be the consequence of conformational changes, for example, by different peptide folding in complex with HLA class I or direct interactions between replaced amino acids and TCR residues. Importantly, when CD8 ϩ T cells were primed in vitro, there was almost no cross-reactivity between sequence variants of the two distinct HCV subtypes 1a and 1b, suggesting that CD8 ϩ T cell responses directed against the NS3 1406 -1415 epitope are typically specific for one subtype only. The lack of cross-reactivity of HCVspecific CD8 ϩ T cells across genotypes and subtypes is well known in HCV immunology (6, 26) and may be the reason why certain HLA class I alleles are associated with protective immunity against HCV only in the setting of individual genotypes or subtypes (7, 8) . Minor sequence differences in immunodominant CD8 ϩ T cell epitopes can have a profound influence on the ability to achieve immune control of HCV (9) . For design of a prophylactic vaccine, this suggests that antigen coverage of different genotypes and possibly even different subtypes may be required to achieve broad protection.
Despite the lack of cross-reactivity of the in vitro-primed CD8 ϩ T cells directed against NS3 1406 -1415 between HCV subtypes 1a and 1b, there was substantial cross-reactivity between epitope variants within genotype 1b. Importantly, the degree of crossreactivity strongly depended on the epitope variant that was used for priming of CD8 ϩ T cells. The epitope variant associated with the highest degree of cross-reactivity was gt1b_3 (KLSALGLN AV). This epitope variant was also associated with the highest level of reproducibility of CD8 T cell priming. The ability to reproducibly prime naive CD8 ϩ T cells and the resulting degree of crossreactivity were independently attributed to different epitope variants and are not explained by different HLA class I-binding affinities, as all peptides tested here were high-affinity binders to HLA-A*02:01. In contrast to the high degree of cross-reactivity of CD8 ϩ T cells primed with the variant gt1b_3, the variant gt1b_AD was also associated with a high level of reproducibility of successful priming; however, despite up to 20% of the CD8 ϩ T cells being reactive to this variant, these cells were not cross-reactive with any other epitope variant. This suggests that the T cell repertoire recruited for targeting of both variants was distinct. TCR V␤ usage was determined by flow cytometry utilizing a panel of V␤-specific
FIG 6
The epitope variant gt1b_3 is enriched in HCV genotype 1b isolates from Asia. All available HCV genotype 1b NS3 sequences were retrieved from the public HCV sequence database. Identical sequences and sequences of unknown origin were removed, and additional sequences obtained in Germany and China were added and aligned. A phylogenetic tree was calculated by utilizing the neighbor-joining method and the Jukes-Cantor distance model. Branches were transformed into a cladogram, and sequences from Japan and China are shown in red. Sequences carrying the epitope variant gt1b_3 are indicated by black dots.
antibodies. Upon priming with gt1b_AD, analysis of IFN-␥-producing T cells showed a different and narrowly focused V␤ usage compared to that of CD8 ϩ T cells primed with the gt1b_3 variant in the same individual. Here, the immune response was comprised of CD8 ϩ T cells utilizing multiple different V␤s. This indicates that, depending on the epitope variant used for priming, different TCR repertoires were targeted. Notably, cross-reactivity of gt1b_3-specific CD8 ϩ T cells was not a direct consequence of broader V␤ usage, as all individual V␤s were cross-reactive with the gt1b_1 variant. This suggests that cross-reactivity was determined at the level of individual V␤s, either by polyclonal expansion of multiple distinct TCRs utilizing the same V␤ or by oligoor monoclonal expansion of T cells with a broadly cross-reactive TCR. The plasticity of binding of individual TCRs to peptide-MHC complexes can strongly vary (27) . There are reports of individual TCRs binding to a multiplicity of different peptide ligands in complex with HLA-A*02:01 (28) (29) (30) . Such broadly cross-reactive TCRs would likely be beneficial for protection against highly variable pathogens.
The epitope variant gt1b_3 was also heavily targeted by CD8 ϩ T cells in our cohort of PWID from Germany, although these patients are predominantly exposed to HCV genotypes 1a and 3a, and infections with genotype 1b are less common (data not shown). CD8 ϩ T cells expanded in the presence of gt1b_3 were to some extent cross-reactive with both the most frequent genotype 1a variant, gt1a_1, as well as the most frequent genotype 1b variant, gt1b_1, although cross-reactivity with genotype 1a was uncommon in the in vitro priming experiments. In contrast, CD8 ϩ T cells expanded from HCV-exposed patients in the presence of the genotype 1a variant gt1a_1 showed no or only little cross-reactivity. The protocol used for expansion of CD8 ϩ T cells from HCVexposed patients targets antigen-specific memory T cells, whereas the more complex in vitro priming experiments targeted the naive CD8 ϩ T cell repertoire. Assuming that the memory T cell responses and cross-reactivity profiles of patients are similarly influenced by the epitope variant at the time of transmission, the high level of reproducibility of specific CD8 ϩ T cell responses directed against gt1b_3 was unexpected, as this epitope variant is rare in German HCV genotype 1b isolates. It is possible that the epitope variant was present as a minority in the quasispecies of infected patients or that priming with a distinct variant not tested here may have driven such CD8 ϩ T cell responses and the observed crossreactivity profiles. As the exact sequence at the time of transmission is unknown, this is difficult to address in patient samples.
Our results indicate that even if an immune response against the most frequent variant, gt1b_1, is the goal, it is still beneficial to use the gt1b_3 variant for priming. For vaccine design, this implies that the optimal antigen sequence for immunization is not necessarily the most frequent epitope sequence in circulating isolates in a population. The concept of using altered peptide ligands for immunization and priming of cross-reactive CD8 ϩ T cells is well described in cancer immunology (27, 31, 32) . Such altered peptide ligands, associated with better priming potential and broader cross-reactivity, are potentially also beneficial for immunization against highly variable pathogens. RNA viruses such as HCV and HIV have the ability to rapidly adapt to CD8 ϩ T cell immune pressure, and there is evidence at the population level that circulating isolates have already adapted to selection pressure by frequent HLA class I alleles (33) (34) (35) (36) . Accordingly, altering the antigen sequence by reconstruction of ancestral states (37) may enhance immunogenicity, as has been demonstrated for HCV (38) . Although not formally tested, it is possible that the most frequent genotype 1b variant (gt1b_1) is already the product of immune selection pressure in the presence of HLA-A*02:01. This would be in line with our observation that the variant associated with the best immunogenicity profile in the context of HLA-A*02:01 was more frequent in Japanese and Chinese isolates. Although HLA-A*02:01 is also frequent in China and Japan (allele frequencies of 0.11 to 0.16 according to the Allele Frequency Net Database [http://www.allelefrequencies.net/]), other subtypes, such as A*02:03, A*02:06, and A*02:07, are collectively as frequent (cumulative allele frequency of 0.12 to 0.17). In Caucasian populations, the frequency of HLA-A*02:01 is two times higher (allele frequency of about 0.27), whereas other subtypes are almost absent. It therefore seems possible that the gt1b_3 epitope variant from Asia was simply not yet fully adapted to HLA*02:01-associated selection pressure and was thus superior in the context of this allele. Unfortunately, when we aimed to perform priming experiments utilizing naive CD8 ϩ T cells from HLA-A*02:non-01 donors, we were unable to identify an individual with such an allele. Therefore, this needs to be addressed in sequence and immunogenicity studies in Asian populations.
Taken together, we show that different naturally occurring variants of the same immunodominant CD8 ϩ T cell epitope in HCV show distinct priming capacities and cross-reactivity profiles. The epitope variant with the best immunogenicity profile of the variants tested was rare in circulating HCV genotype 1b isolates from Europe and North America. For vaccine design against highly variable pathogens such as HCV and HIV that share the ability to adapt to CD8 ϩ T cell immune pressure, the results are highly relevant, as they suggest that cross-reactivity profiles of T cells may be influenced by the antigen sequence used in a vaccine. Our data indicate that besides optimizing antigen processing and HLA class I presentation, both of which are required for an efficient CD8 T cell-based vaccine, a biological assay will provide experimental evidence for the choice of more subtle amino acid exchanges within the sequence. By using one particular HCV epitope as a proof of principle, our study suggests that evidencebased selection of the optimal antigen sequence can enhance both immunogenicity of a vaccine and cross-reactivity of CD8 T cells in humans. To this end, rare epitope variants and potentially even altered epitope sequences associated with priming of broadly cross-reactive TCRs should be considered and need further testing.
